Pau Gorostiza, principal investigator at IBEC and ICREA profesor, appears in the media for his study co-led with Tobias Moser, director of the Institute for Auditory Neuroscience. The study presents the first light-controlled drug that produces auditory stimulation in vivo without the need of genetic manipulation.
This new light-controlled drug, capable of activating neural pathways involved in hearing, may help improve the spectral resolution of cochlear implants used by people with profound hearing loss or deafness.
The breakthrough, published in the Journal of the American Chemical Society (JACS), presents a new generation of cochlear implants that would reduce difficulties in following conversations when there is a lot of background noise and limited music appreciation.
Tobias Moser’s group has pioneered research in this area, and they have successfully restored hearing with light by genetically modifying spiral ganglion neurons.
You can read all the impacts here: